Listen to this article

White House Demands 85% Drug Price Cuts as Biopharma Faces Stealth Setback, FDA Rare Disease Issues, and Tariff Challenges

4 posts • GPT (4.1 mini)

Updated May 31, 2025, 03:34 AM

The biopharmaceutical industry is facing intense pressure from the White House under President Donald Trump's administration, which is demanding an 85% across-the-board reduction in drug prices as part of its Most Favored Nation (MFN) policy. Industry stakeholders are actively seeking alternative concessions to avoid what they describe as potentially catastrophic policies. This regulatory environment comes amid broader challenges, including setbacks for biotech companies such as Stealth Therapeutics in navigating the U.S. Food and Drug Administration's rare disease policies, exemplified by the difficulties in developing treatments for Barth syndrome.

Meanwhile, discussions continue on how to mitigate the impact of U.S. tariffs on pharmaceutical supply chains and the potential shifts in pricing paradigms for GLP-1 drugs. Experts suggest that following guidance from the Biden administration could lead to lower drug prices and broader access to the benefits of publicly funded scientific research.

More breaking stories on DeepNewz — updated live.

#White House #Donald Trump #Most Favored Nation #Stealth Therapeutics #Barth #Biden

Financial Analysis

Associated Financial Markets

More financial news and market updates→

Related Prediction Markets

Will Trump remove 10% blanket tariff in 2025?

How much spending will DOGE cut in first 6 months?

Trump signs bill cutting Medicare before July?

•

Sources

biocentury.com(3)insights.citeline.com(2)nationalinterest.org

National Interest

@TheNatlInterest

Moving forward with the Biden administration’s guidance could deliver lower drug prices and allow more Americans to reap the benefits of public science, write Jack Corrigan and Vikram Venkatram.

Jeff Cranmer

@jeff_cranmer

The biopharma industry is racing to counter the Trump MFN threat: With White House demanding 85% across-the-board drug price cuts, the biopharma industry hopes to avoid catastrophic policies via alternative concessions, writes @BioCentury's @steveusdin1

BioCentury

@BioCentury

Industry races to counter Trump MFN threat: White House demanding 85% across-the-board drug price cuts as biopharma industry hopes to avoid catastrophic policies via alternative concessions

Story Timeline

1 month ago•Latest version

White House Demands 85% Drug Price Cuts as Biopharma Faces Stealth Setback, FDA Rare Disease Issues, and Tariff Challenges

1 month ago•Original version

Trump Administration's 25% Tariffs and MFN Drug Pricing Plan Could Cost Pharma $76 Billion, Impact Access and GLP-1 Sales

White House Demands 85% Drug Price Cuts as Biopharma Faces Stealth Setback, FDA Rare Disease Issues, and Tariff Challenges

Financial Analysis

Associated Financial Markets

Related Prediction Markets

Will Trump remove 10% blanket tariff in 2025?

How much spending will DOGE cut in first 6 months?

Trump signs bill cutting Medicare before July?

Sources

Story Timeline

Similar Stories